Comprehensive solutions for the pharmaceutical industry
Pharmaceutical Sector.
Plastron have personnel with specific Pharmaceutical expertise to discuss the
services we offer, ranging from the provision of initial consultancy and feasibility studies to
a complete turnkey CRO package.
Microgravity environments can provide unique biological insights and new R&D advantages that directly benefit biotechnology and pharmaceutical companies.
A microgravity environment (like on the International Space Station or in orbital labs) provides
unique physical conditions that can reveal molecular behaviours and biological processes that
are impossible or difficult to observe on Earth. Here's a breakdown of how microgravity benefits
pharmaceutical R&D:
-
Why it matters: Many drugs are designed to target specific proteins. To
understand these targets, scientists grow protein crystals and study them with X-ray
crystallography.
-
In microgravity: Crystals grow more slowly and uniformly, without
sedimentation or convection currents.
-
Result: Larger, more perfect crystals → higher-resolution structures →
better insights for structure-based drug design.
-
Examples:
-
NASA and Merck have crystallized Keytruda (pembrolizumab) in microgravity to
study stability.
-
Eli Lilly and others have flown protein crystallization experiments to improve
drug formulation.
-
Suspension stability: Microgravity allows researchers to study how
particles aggregate or suspend in fluids without sedimentation.
-
Applications:
- Improving nanoparticle drug carriers (e.g., liposomes, emulsions).
-
Understanding diffusion-driven mixing, which is key for injectable or inhalable
drug systems.
-
Outcome: Insights that can lead to longer shelf life and more efficient
delivery mechanisms.
-
Microgravity mimics: Aspects of aging and disease (like bone loss,
muscle atrophy, immune dysfunction) at an accelerated pace.
-
Pharma use:
- Test osteoporosis drugs using rapid bone-density changes in space.
- Study immune and cancer cell behavior under stress-free growth conditions.
-
Example: Space-grown organoids or tissue chips are used to model
diseases such as Parkinson's, ALS, and cancer.
-
In space, cells often behave differently — changes occur in gene expression, metabolism,
and cell signaling.
-
Pharma companies can use this to:
- Identify new therapeutic targets.
- Observe cellular responses to stress, drugs, or radiation more clearly.
- This leads to new insights into human physiology that can inspire new treatments.
-
In the long term, pharma companies could manufacture high-value biologics or materials
in orbit.
-
Examples:
-
Microgravity bioprinting of human tissues for research or transplant testing.
-
Production of ultra-pure crystals or unique biomaterials that degrade on Earth.
-
Differentiation: Access to space research enhances innovation
reputation.
-
Collaboration: Partnerships with NASA, Axiom Space, SpaceX, and others
reduce R&D costs.
-
IP Advantage: Proprietary findings from space experiments can create
competitive drug pipelines.
Summary Table
| Area |
Microgravity Advantage |
Pharma Outcome |
| Protein Crystallization |
Larger, more uniform crystals |
Better structural data for drug design |
| Drug Formulation |
No sedimentation or convection |
Improved delivery systems |
| Disease Modeling |
Accelerated cellular/aging effects |
Faster preclinical insights |
| Cell Biology |
Unique gene/protein expression |
New therapeutic targets |
| Biomanufacturing |
Novel physical behaviors |
New materials or drugs |
| Strategic Value |
Prestige, partnerships |
Long-term innovation |
